For anyone who listened to today's JPM call, the company was very cautious and hedged quite a bit on when SCD data would be released. Sounds like more b-thal at EHA and SCD at ASH. So don't get your hopes up that we see SCD at EHA. Not to worry though, the stock will continue to rise into EHA and when even more positive news on b-thal comes out, it will rise even further. Won't be surprised to see near $200 just before ASH, and that's without SCD data.
Please give 10 examples of a company paying above market price with a new share issuance. Even better, let's use your example of 50% above market price. I'll be waiting for your response. Thanks in advance.
P.S. You really shouldn't be calling anyone dumb. Pot meet kettle.
P.P.S. Are you a paid pumper? Because you're spewing every kind of phony baloney from a pump-job handbook.
What are you smoking? If a stock is trading at $5, there's ABSOLUTELY NO WAY any fund is going to buy more at $7.50. Issuing shares is ALWAYS dilutive. That dilution may or may not be bad, depending on the circumstances. If a company has good fundamentals and needs to raise cash, the market will see the new shares as a positive (e.g., BLUE). If a company is a P.O.S. and issues more shares to raise cash, the market will destroy the stock (e.g., HEB). Even with positively received cash raises, the market cap will be less for at least a few weeks. It's highly, highly, highly unlikely that it will suddenly be higher, as you are suggesting with your extremely awful, unrealistic example.
I recently bought SQNM because the chart looks great, and the company has a lot going for it fundamentally, but ignorant investors like you make me want to sell. Your kind is typically a huge red flag. And by "your kind," I mean anyone who refuses to look at a situation objectively. You are ruled by emotions, and that isn't good when it comes to the stock market. That being said, I'm not going sell, but you really need to take a chill pill.
We highlight bluebird bio (ticker: BLUE ) (rated at Outperform) as an example of a company performing groundbreaking research with potentially an accelerated development path ahead. Bluebird’s gene therapies for severe inherited diseases have curative potential, and we forecast the time to approval to be less than five years since the start of clinical studies. Bluebird’s LentiGlobin has received Breakthrough Therapy for the treatment of beta-thalassemia, and we expect disease modifying activity in sickle cell to be announced later this year.
Even in the case of a major correction, we believe merger and acquisition (M&A) interest could continue and help buoy the sector. M&A activity has intensified in recent years, as big pharma becomes increasingly reliant on acquisitions to replenish its pipeline. Given the declining research-and-development productivity in pharma, acquiring external therapies that have been validated in the clinic, even at a premium, appears to be a sounder investment strategy than focusing on in-house development. However we see signs that the valuations in commercial biotech companies have run up to levels that are dissuading potential acquirers, who may now be waiting for assets to become less expensive. We believe any major correction in the biotech sector could provide the right entry point for these would-be acquirers. We highlight Medivation ( MDVN ) (rated at Outperform) and Anacor Pharmaceuticals ( ANAC ) (rated at Outperform) as potential acquisition targets, given that each have commercial products with room to grow in large market opportunities.
Um, your DD is horrible. Cramer first told investors to buy RCPT in the middle of January. It takes 30 seconds for you to find that out using Google. And yes, believe it or not, the stock is still a strong buy at these levels. If you bought higher last week and then sold for a loss, well, that's your fault. The stock will be well above $200 by the end of the year.
You got that right, brother! Thanks for looking out for everybody, willie. Your altruism is appreciated.
I bet Cramer makes far more money than you. He told investors to buy in the low $100s. Please explain how a 50% return in four months amounts to poor credibility. Thanks in advance.
Because the company is about to go bankrupt. Best to save yourself the misery and take your loss now. Sorry boo, I know you were expecting more.
We get it, willie. You "coincidentally" appeared shortly after CG was fired and are here to sow seeds of doubt. Zzzzz....
No penalty for younger people if it's a conversion directly into a Roth IRA. You simply have to pay tax on the conversion for the tax year that you made the conversion. The amount of the conversion is just counted as income for the year, even though you aren't technically receiving it that year.
No, they don't, blank. The FDA has yet to formally request the 4th biopsies. Until they do that, it is at the company's discretion as to whether or not to include them.
The FDA said nothing about requiring a 4th biopsy. It was the company's decision because they feel it will help their cause. And if dystrophin is present, it will.
Yes. In fact, that was my first thought. He went all in on dystrophin and the 4th biopsy and didn't push for 6MWT as hard as he should have. So it would make sense that if the 4th biopsy did not look all that great, he'd be axed quickly. That being said, I don't necessarily think that's the reason he was let go. At least, I hope not. I think biopsies should be okay, but it's certainly not a guarantee.